Do-Youn Oh

Do-Youn Oh is a leading Korean oncologist specializing in biliary tract cancers who contributed to the TOPAZ-1 trial establishing durvalumab plus gemcitabine and cisplatin as a new first-line standard for advanced biliary tract cancers including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. His research has characterized the molecular epidemiology of biliary tract cancers in Korean and broader East Asian populations, including FGFR2 fusions and IDH1 mutations in intrahepatic cholangiocarcinoma and HER2 amplifications in gallbladder cancer. He has participated in pivotal trials of targeted therapies including pemigatinib and ivosidenib for FGFR2-fused and IDH1-mutated cholangiocarcinoma in Asian populations. His contributions to the Asia-Pacific biliary cancer research network have advanced clinical trial conduct and access to innovative therapies in East Asia.